AbbVie Announced Topline Results From Phase 3 SEQUENCE Trial Of Skyrizi (Risankizumab) Versus Stelara (Ustekinumab); The Study Met Its Primary Endpoint In Patients With Moderately To Severely Active Crohn's Disease Who Have Failed One Or More Anti-TNFs
Portfolio Pulse from Benzinga Newsdesk
AbbVie has announced positive topline results from its Phase 3 SEQUENCE trial of Skyrizi (Risankizumab) versus Stelara (Ustekinumab). The study met its primary endpoint in patients with moderately to severely active Crohn's disease who have failed one or more anti-TNFs.
September 12, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The positive results from the Phase 3 SEQUENCE trial of Skyrizi could potentially boost AbbVie's market position in the treatment of Crohn's disease.
The successful completion of the Phase 3 trial and meeting its primary endpoint indicates that Skyrizi could be a potential new treatment for Crohn's disease. This could lead to increased revenues for AbbVie, thus potentially boosting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100